Tracers / [177Lu]Lu-Comb-2
[177Lu]Lu-Comb-2
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated chimeric peptide (DOTA-PEG6-d-PepH3-TPP)
- Target / mechanism
- Targets membrane-bound heat shock protein 70 (mHsp70), overexpressed in glioblastoma, via the TPP sequence PMID 42306550
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | HPLC | — | ≥95% | DOTA-PEG6-d-PepH3-TPP (Comb-2) | 42306550 2026 Chem Sci each compound (1 µL, 1 mM in DMSO) was added to 10 µL of sodium acetate buffer |
Need this precursor?We can point you to suppliers for [177Lu]Lu-Comb-2, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 42306550. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 42306550: 'Comb-2 (DOTA-PEG6-d-PepH3-TPP)'.